Introduction {#sec1-1}
============

Breast cancer is the most frequent cause of cancer-related death among women worldwide, claiming more than 400,000 lives every year (Jemal et al., 2011). In India, a rising trend in breast cancer incidence is observed, which is predicted to 31% rise by 2020 (Anonymous, 2009). Breast cancer is a biologically and clinically heterogeneous disease where gene/pathway function changes with specific genetic and epigenetic alterations (Hanahan and Weinberg, 2011). Thus, understanding the contribution of gene expression in profiling the clinical subgroups and their assessment as prognostic factors are of great importance in the prediction of the disease.

*PTEN* (Phosphatase and tensin homolog) gene, located on chromosome 10 is a well-known tumor suppressor gene, which is frequently altered in a wide spectrum of cancers (Li et al., 1997; Steck et al., 1997). It is a lipid phosphatase, which negatively regulates PI3K-AKT pathway, thereby regulating a plethora of various cellular processes like cell cycle, apoptosis, cell survival, cell growth, adhesion, migration and spreading (Vivanco and Sawyers, 2002; Lu et al., 1999; Tamura et al., 1998). *PTEN* expression and function are usually altered in cancer by genetic and epigenetic alterations. *PTEN* has been found to be linked with the breast cancer initiation and progression through a number of mechanisms such as mutation, loss of heterozygosity at the *PTEN* gene locus, epigenetic silencing of *PTEN* promoter and posttranslational modifications (Song et al., 2012; Salmenaet al., 2008). Recently, *PTEN* alteration was found to be associated with an emerging tumor suppressor gene, Parkin, which opened a new horizon to its regulation (Wahabiet al., 2018). In case of breast cancer, structural mutations of the *PTEN* gene are very rare while familial cancer syndrome known as Cowden disease has 25% to 50% lifetime risk of developing breast cancer (Nelen et al., 1999; Lynch et al., 1997). Loss of heterozygosity (LOH) at *PTEN* (10q23) locus is approximately 30--40% (Singh et al., 1998). Additionally, *PTEN* promoter methylation has been suggested as one of the most common molecular alterations involved in the pathogenesis of various malignancies including breast cancer (Shetty et al., 2011; Zhang et al., 2013).

Molecular classifications are indicators of genetic tumor heterogeneity, which can lead to improved stratification of cancer into low- and high-risk groups for personalized therapy. Despite several types of research conducted globally on *PTEN* gene implications in breast cancer, the exact mechanism of altered *PTEN* involvement and its association with clinical variables in breast cancer is not well established in Indian patients. Keeping the significance of the *PTEN* gene in breast cancer initiation and prognosis, in view, the present study aims to evaluate the *PTEN* gene abnormalities and its association with distinct clinical parameters in north Indian breast cancer patients.

Materials and Methods {#sec1-2}
=====================

Ethics Statement {#sec2-1}
----------------

The present study was approved by the Institutional Ethics Committee (IEC) of Jamia Millia Islamia, New Delhi. A written informed consent as approved by the IEC was obtained from all the participants of the study.

Breast tissue samples and DNA extraction {#sec2-2}
----------------------------------------

A total of one hundred and eighty one (n=181) invasive breast carcinoma samples along with their adjacent noncancerous tissues were collected after mastectomy from LNJP Hospital, New Delhi, along with their associated clinicopathological parameters. Biopsies were divided into two parts; one part was placed in a Phosphate saline buffer (PBS; pH=7.2) and stored as soon as possible in -80 °C for DNA extraction. The other part was collected in 10% formalin for histopathological investigations. Genomic DNA was extracted by using ZR Genomic DNATM MiniPrep Kit (Zymo research, USA) according to manufacturer's protocol. The quantity and quality of the DNA were determined by the Nanodrop (Thermo Fisher Scientific, USA) Spectrophotometer and further by running 1 % agarose gel stained with ethidium bromide.

PTEN allelotyping; estimation of heterozygosity {#sec2-3}
-----------------------------------------------

DNA from tumor and non-tumor samples was amplified using three published polymorphic microsatellite markers located within and close to the *PTEN* gene to detect loss of heterozygosity (LOH). Markers D10S215 and D10S583 are located within the *PTEN* gene, while, the D10S541 marker is found at the flanking region. Briefly, PCR reactions were performed in 25 µl volumes with a final concentration of 200 µM dNTP, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.4 µM of each primer, 0.5 units of Taq DNA polymerase (BangloGenei, India) and 60 ng of DNA template. The sequence of the primers is shown in supplementary [table 1](#T1){ref-type="table"}. PCR was done and the products were resolved ([Figure 1](#F1){ref-type="fig"}) as described previously (Rizvi et al., 2012).

###### 

Correlation of the PTEN Protein Expression with LOH and Promoter Methylation

                  Total (Cases)   PTEN Expression   P value                       
  --------------- --------------- ----------------- --------- --------- --------- ----------
  PTEN gene                                                                       
   Without LOH    83 (46)         35 (42)           16 (19)   14 (17)   18 (22)   \<0.0001
   With LOH       98 (54)         62 (63)           33 (34)   3 (3)     0 (0.0)   
   Total          181 (100)       97 (54)           49 (27)   17 (9)    18 (10)   
  PTEN promoter                                                                   
   Unmethylated   87 (48)         38 (44)           25 (29)   7 (8)     17 (20)   0.002
   Methylated     94 (52)         59 (63)           24 (26)   10 (11)   1 (1)     
   Total          181 (100)       97 (54)           49 (27)   17 (9)    18 (10)   

![Loss of Heterozygosity (LOH) at Each of the Three Loci of 10q23 Region in Breast Cancer. (A) Silver-stained polyacrylamide gel containing amplified product from the normal mucosa (N) and tumor (T) of patients (identified by numbers) with breast cancer. The tumors from patients 7, 23 and 49 showing loss of heterozygosity at different loci studied in the PTEN gene (arrowhead) while, patient 14 did not show the LOH and patient 53 was uninformative. All photographs are cropped and inverted to a white background for clarity. (B) Bar diagram showing the comparison of frequencies of LOH detected at three microsatellite markers in tumor samples from patients with breast cancer.](APJCP-20-269-g001){#F1}

PCR-SSCP analysis {#sec2-4}
-----------------

Isolated genomic DNAs were subjected to PCR-SSCP for mutational analysis. The primers and conditions used for the different *PTEN* exons were as described in an earlier study (Rizvi et al., 2011). The PCR products were resolved in 2% agarose gels and visualized by staining with ethidium bromide. Non-radioisotopic SSCP analysis was performed as previously described (Rizvi et al., 2011). After electrophoresis, silver staining was done for visualization. PCR products that revealed mobility shifts on SSCP analysis were sequenced for mutation.

Bisulfite modification of DNA and MS-PCR {#sec2-5}
----------------------------------------

Genomic DNA from breast cancer and normal specimens were modified by treatment with sodium bisulfite using EZ DNA Methylation-Gold kit (Zymo Research, USA) according to manufacturer's protocol. Two separate sets of primers were used for the amplification of the promoter region of the *PTEN* gene, one primer specific for unmethylated sequence 5'GTGTTGGTGGAGGTAGTTGTTT-3'(sense) and 5'- CCACTTAACTCTAAACCACAACCA-3'(antisense) was used to amplify a 162 bp product, while the other primer specific for methylated sequence 5'-TTCGTTCGTCGTCGTCGTATTT-3'(sense) and 5'-GCCGCTTAACTCTAAACCGCAACCG-3'(antisense) was used to amplify 206-bp product. Completely methylated and unmethylated human genomic DNA (Zymo Research Corp., Orange, CA) were used as positive control for the methylated allele ([Figure 2](#F2){ref-type="fig"}).

![MS-PCR Gel Picture, Representing Promoter Hypermethylation of PTEN Gene in Breast Cancer. The lanes T1 to N2 correspond to DNA from patients with breast cancer; L, Ladder 100bp; U, Unmethylated PTEN promoter (product size 162 bp); M, Methylated *PTEN* promoter (product size-206 bp); PC, positive control for unmethylated and methylated alleles (completely unmethylated and methylated DNA controls, respectively); N, normal tissue sample; T, tumor tissue sample.](APJCP-20-269-g002){#F2}

PTEN Immunohistochemistry {#sec2-6}
-------------------------

Paraffin-embedded blocks were made from formalin-fixed tissues. The sectioning was done by microtome and fixed on glass slides. The whole procedure was followed as mentioned in an earlier study (Ali et al., 2014) using anti-*PTEN* (Thermofisher) antibody (1:100). Afterward, slides were incubated with biotinylated horse anti-mouse IgG followed by avidin-peroxidase. The reaction was then visualized with diaminobenzidine (DAB). Hematoxylin was used as a counterstain. Each run included appropriate positive and negative control slides. Representative pictures are shown in [Figure 3](#F3){ref-type="fig"}.

![Representative Pictures of Immunostaining of *PTEN* Protein Expression in Human Breast Tissue Samples; (A) Normal breast tissue showing strong PTEN expression, (B) Breast cancer tissue showing negative expression of PTEN, (C) Breast cancer tissue showing low expression of PTEN protein.(D) & (E) showing moderate to high expression of PTEN expression in breast cancer tissue. (magnification: 400X, scale bar 1000 µm). PTEN-positive staining is generally detected cytoplasmic signal that can easily be distinguished from PTEN-negative cases. In the presented example images, 3,3′-Diaminobenzidine (DAB) was used as a chromogen.](APJCP-20-269-g003){#F3}

Interpretation of staining {#sec2-7}
--------------------------

Slides were evaluated by an expert histopathologist under a light microscope at 400X magnification ([Figure 3](#F3){ref-type="fig"}). Stained slides were graded as negative (0), low expression (up to 25%), moderate expression (up to 50%), and high expression (more than 50%). Furthermore, if the expression of a protein was more than 5% only then it was considered a positive case.

Statistical analysis {#sec2-8}
--------------------

All the statistical comparisons were performed with Fisher's exact test for significance. P-values p\<0.05 were accepted as statistically significant.

Results {#sec1-3}
=======

PTEN allelotyping and correlation with clinical parameters of breast cancer {#sec2-9}
---------------------------------------------------------------------------

Three markers viz D10S215, D10S583, and D10S541 ([Table.1](#T2){ref-type="table"}) were used to investigate LOH at 10q23 region. 54% (98/181) cases showed loss of heterozygosity at the 10q region. The highest rate of LOH (31%) was observed at intragenic marker D10S583 when compared with either loci within (D10S215) gene (26%) or flanking region of the gene (23%) as summarized in [Figure 1](#F1){ref-type="fig"}. LOH was significantly associated with age \[P= 0.0018, \<50 (65%) vs ≥50 (42%) cases\], advanced clinical stage \[P\< 0.0001, stage III+IV (81%) vs stage I+II (38%)\] and ER positivity \[P=0.0197, ER positive (75%) vs ER negative (50%) cases\] (Supplementary [Table 2](#T2){ref-type="table"}) .

###### 

Correlation Analysis of *PTEN* Protein Expression and Methylation in Samples Having Methylated *PTEN* Promoter or *PTEN* Loss in Indian Breast Cancer

  Clinical Parameters   Total (N=73)   PTEN Methylated   *P-value*   Total (N=108)   PTEN loss   *p-value*             
  --------------------- -------------- ----------------- ----------- --------------- ----------- ----------- --------- -------
  Age                                                                                                                  
   \<50                 48             27 (56)           27 (56)     0.206           47          20 (43)     27 (57)   0.539
   ≥50                  46             32 (70)           32 (70)                     50          18 (36)     32 (64)   
  Menopausal Status                                                                                                    
   Premenopausal        34             14 (41)           14 (41)     0.002           24          10 (42)     14 (58)   0.812
   Postmenopausal       60             45 (75)           45 (75)                     73          28 (38)     45 (62)   
  Tumor Size                                                                                                           
   \<2cm                21             12 (57)           12 (57)     0.612           23          11 (48)     12 (52)   0.341
   \>2cm                73             47 (64)           47 (64)                     74          27 (36)     47 (64)   
  Clinical Stage                                                                                                       
   I+II                 48             31 (65)           31 (65)     0.831           63          32 (51)     31 (49)   0.002
   III+IV               46             28 (61)           28 (61)                     34          6 (18)      28 (82)   
  Histological grade                                                                                                   
   I+II                 63             33 (52)           33 (52)     0.003           56          23 (41)     33 (59)   0.689
   III+IV               31             26 (84)           26 (84)                     41          15 (37)     26 (63)   
  ER Status                                                                                                            
   Negative             75             52 (69)           52 (69)     0.015           85          33 (39)     52 (61)   1
   Positive             19             7 (37)            7 (37)                      12          5 (42)      7 (58)    
  PR Status                                                                                                            
   Negative             70             46 (66)           46 (66)     0.337           73          27 (37)     46 (63)   0.477
   Positive             24             13 (54)           13 (54)                     24          11 (46)     13 (54)   
  HER2 Status                                                                                                          
   Negative             32             27 (84)           5 (16)      0.002           40          13 (32)     27 (68)   0.296
   Positive             62             32 (52)           30 (48)                     57          25 (44)     32 (56)   
  TNBC                                                                                                                 
   Negative             61             31 (5)            30 (49)                     53          22 (41)     31 (59)   0.678
   Positive             33             28 (85)           5 (15)      0.002           44          16 (36)     28 (64)   

PTEN promoter methylation and correlation with clinical parameters of breast cancer {#sec2-10}
-----------------------------------------------------------------------------------

Overall, we found 51.9% (94/181) *PTEN* promoter methylation. *PTEN* promoter methylation was significantly correlated with advancing age \[P\< 0.0001, \>50 (79%) vs \<50 (27%) cases\], Clinical stage \[P= 0.0001, stage III+IV (71%) vs stage I+II (40%)\] advanced histological grade \[P= 0.0001, grade III+IV (74%) vs grade I+II (42%)\] and Her-2 negative status \[P=0.003, Her2 negative (69%) vs Her2 positive (45%) cases\] as described in Supplementary [Table 3](#T3){ref-type="table"}.

###### 

Statistical Relation between *PTEN* Gene Status and *PTEN* Protein Expression in Indian Breast Cancer

  PTEN gene status                Total (n=181)   *PTEN* Expression   p Value                    
  ------------------------------- --------------- ------------------- --------- -------- ------- -------
  Double hit Methylation+ LOH     46 (25)         32 (70)             12 (26)   2 (4)    0 (0)   0.037
  Single hit (Methylation only)   48 (27)         27 (56)             12 (25)   8 (17)   1 (2)   
  Single hit LOH only             52 (29)         30 (58)             21 (40)   1 (2)    0 (0)   

PTEN expression and correlation with clinical parameters of breast cancer {#sec2-11}
-------------------------------------------------------------------------

Out of 181 breast cancer tissue samples 54% (97/181) cases showed loss of *PTEN* protein expression. Loss of *PTEN* expression was significantly correlated with post-menopausal status \[P \<0.0001, postmenopausal (68%) vs premenopausal (33%) cases\], Clinical stage \[P=0.0086, stage I+II (56%) vs stage III+IV (49%)\], advanced histological grade \[P=0.0081, grade III+IV (71.9%) vs grade I+II (45%)\], Her-2 negative status \[P\<0.0001, Her2 negative (77%) vs Her2 positive (44%) cases\] and triple negative cases \[P=0.0043, TNBC (82%) vs TPBC (57%) cases\] as shown in Supplementary [Table 4](#T4){ref-type="table"}.

###### 

Correlation of *PTEN* Protein Expression with TNBC Cases in a Subgroup Consists of Tumor Size and Menopausal Status

  Menopausal Status   Tumor size   TNBC Status   Total     *PTEN* Expression   p Value   
  ------------------- ------------ ------------- --------- ------------------- --------- -------
  Premenopausal       \<2cm        Negative      15        5 (33)              10 (68)   1
  Positve             5            2 (40)        3 (60)                                  
  \>2cm               Negative     36            9 (25)    27 (75)             0.127     
  Positive            17           8 (47)        9 (53)                                  
  Postmenopausal      \<2cm        Negative      15        10 (67)             5 (33)    0.262
  Positive            6            6 (100)       0                                       
  \>2cm               Negative     57            29 (51)   28 (49)             0.0001    
  Positive            30           28 (93)       2 (7)                                   

PTEN allelotyping and correlation with PTEN protein expression of breast cancer {#sec2-12}
-------------------------------------------------------------------------------

In the present study, 54% (98/181) breast cancer cases showed LOH in the 10q23 region. On the other hand, 54% (97/181) cases have shown loss of *PTEN* protein expression. Interestingly, a statistically significant relationship was found between the LOH and Loss of *PTEN* protein expression \[P= \<0.0001, *PTEN* negative (63%) vs *PTEN* positive {Low (34%), Moderate(3%), High(0%)} cases\] as summarized in [Table 1](#T1){ref-type="table"}. We also evaluated the correlation of *PTEN* expression with clinical variables in LOH positive cases and found significant correlations of *PTEN* loss with menopausal status, Her-2 negativity, and TNBC cases. On the contrary, in *PTEN* negative cases, LOH showed no correlation with any clinical variable (Supplementary Table 5).

PTEN promoter methylation and correlation with PTEN protein expression of breast cancer {#sec2-13}
---------------------------------------------------------------------------------------

Out of 181 sporadic breast cancer cases, promoter methylation of *PTEN* was observed in 52% (94/181) cases. Moreover, *PTEN* promoter methylation was found to demonstrate a significant level of association with the *PTEN* protein loss \[P= 0.002, *PTEN* negative (63%) vs *PTEN* positive {Low (26%), Moderate(11), High(1)} cases\]. Moreover, in *PTEN* negative cases level of promoter hypermethylation was higher than unmethylated cases (i.e., 63% vs 44%) as illustrated in [Table 1](#T1){ref-type="table"}. While correlating the *PTEN* expression in methylated cases, we observed a significant correlation of it with menopausal status, histological grade, ER status, Her-2 status and TNBC cases. In contrast, in *PTEN* negative cases, *PTEN* methylation showed a significant correlation only with clinical stage ([Table 2](#T2){ref-type="table"}).

PTEN mutation screening {#sec2-14}
-----------------------

The entire coding region of *PTEN* was screened. For each tumor and control samples, all nine exons were amplified. PCR products having altered mobility were directly sequenced. Based on our *PTEN* sequencing results, we found only 7% mutation in the north Indian population. Apparently, no significant correlation was found between the mutation and clinical variables.

PTEN expression status in methylation and LOH cases; two hit {#sec2-15}
------------------------------------------------------------

There were 25% (46/181) cases in the present study, which harbored double hit (i.e, having both LOH and *PTEN* methylation). In these cases, 70% (32/46) showed a dramatic loss of *PTEN* protein expression, thereby complete inactivation of *PTEN* gene as shown in Table 8. Although there were 26% (12/46) and 4% (2/46) cases which shown low and moderate expression of *PTEN* in spite of double hit ([Table 3](#T3){ref-type="table"}). This could be explained by an insufficient methylation at the promoter site and indicate that a certain level of methylation is needed for translational inactivation and silencing. We found that molecular events like LOH and methylation of *PTEN* gene play important role in breast cancer patient and have an immense impact on clinical variables.

Association of PTEN expression with clinical subgroups {#sec2-16}
------------------------------------------------------

Interestingly, we found a significant correlation between *PTEN* loss and menopausal status, which remains significant even in LOH positive and in *PTEN* methylated cases ([Table 2](#T2){ref-type="table"}) (Supplementary Table 5). To get a closer relationship, we further divided samples into premenopausal and postmenopausal cases. Where in premenopausal cases, we found a significant correlation of *PTEN* positive cases with clinical stage and histological grade while in postmenopausal cases, loss of *PTEN* expression showed significant correlation with advanced histological grade, ER negativity, Her-2 negativity and TNBC cases (Supplementary Table 6). To check the effect of tumor size, we also divided group in small and large tuomor sizes and found significant associations of *PTEN* with different variables (Supplementary Table 7). Finally, we examined the association of *PTEN* expression with TNBC cases in a combined group of menopausal status and Tumor size, where loss of *PTEN* expression was significantly correlated with the triple negative breast cancer of large tumor size in postmenopausal group ([Table 3](#T3){ref-type="table"}).

Discussion {#sec1-4}
==========

*PTEN* aberration is frequently observed in human solid cancer, including breast cancer (Salmena et al., 2008). It is reported that *PTEN* demonstrates tumor suppression through the regulation of PIP3 in PI3K/Akt pathway (Maehama and Dixon, 1998). In addition to genetic implication, the epigenetic crosstalk also plays a crucial role in breast cancer (Polyak, 2011). In the present study, we, therefore, investigated mutation, loss of heterozygosity, methylation status of the *PTEN* promoter region and their association with the expression level of *PTEN* protein. We further analyzed how different molecular aberrations of the *PTEN* gene are correlated with different clinicopathological parameters and define subgroups among north Indian breast cancer patients.

Through the immunostaining, we observed a 54% (97/181) loss of in *PTEN* protein expression as compared to normal controls which are in agreement with earlier studies reporting 33% -45% loss of *PTEN* protein in the breast cancers (Perren et al., 1999; Bose et al., 2002; Inanc et al., 2014). Notably, we found a significant relationship of *PTEN* loss with menopausal status, clinical stage, histological grade, Her-2 negativity and TNBC (triple-negative breast cancer). Interestingly, in the present study, 32% (58/181) cases were TNBC (triple-negative breast cancer) and out of which, 76% (44/181) cases were also 'Quadruple Negative' (ER, PR, Her-2 and *PTEN* negative). Thus, we confirm *PTEN* loss a frequent event in Indian TNBC cases; that identified *PTEN* immunohistochemistry as an important tool in the TNBC group. In view of that *PTEN* loss may be a predictive marker for the treatment response.

Our study also speculates possible genetic and epigenetic factors involved in *PTEN* loss. We observed a comparatively higher (54%) LOH at *PTEN* region than previous studies (Singh et al., 1998; Rizvi et al., 2012; Feilotter et al., 1999), which was found to be significantly correlated with the loss of *PTEN* expression. Although, like other studies, we found very less (\~7%) cases of mutation in Indian patient (Li et al., 1997; Tashiro et al., 1997; Guldberg et al., 1997). In addition, we noted 51.9% (94/181) *PTEN* promoter methylation that was also significantly related to the loss of *PTEN* protein. This pattern is again supported by several pieces of evidence (Zhang et al., 2013; García et al., 2004). Our finding is congruent with an earlier study (Siddiqu et al., 2016) which have close pattern resemblance of *PTEN* expression and promoter methylation but their study lacks comprehensive illustration especially on the aspect of LOH which we have extensively evaluated in addition to the parameters taken by them (Siddiqui et al., 2016). In line with this, we also checked the combined effect (double hit) of *PTEN* methylation and LOH in *PTEN* loss. It is noteworthy, 25% (46/181) cases showed concomitant LOH and *PTEN* promoter hypermethylation. Among these 25% samples, 70% (32/46) cases had complete expressional loss of *PTEN*. However, despite the double hit, we have found a low 26% (12/46) and medium 4% (2/46) expression of *PTEN* protein. The incomplete methylation at the promoter site could account for this low expression. Hence, our study provides an evidence that besides the double hit, both LOH and methylation of *PTEN* promoter are major the independent mechanism leading to loss of *PTEN* protein at least in north Indian population.

To determine whether pathologic features can define a subset of women who are likely to have *PTEN* alterations, we correlated the molecular events with patients variables. Like an earlier study, we found that allelic loss at 10q23 region is more prevalent among patients less than 50 years of age, however, in contrast to the study, our result also underlines the implication of advanced clinical stage and ER positivity in Indian breast cancer patients (Garcia et al., 1999). We also found a significant role of *PTEN* methylation in tumor progression. In addition, loss of *PTEN* expression has shown a strong relationship with menopausal status and TNBC even after grouping in LOH positive and *PTEN* methylation subgroups. Our study also found that significantly correlated Quadruple group (TNBC+*PTEN* negative) is predominantly found in tumors of the large size of a postmenopausal subset.

To the best of our knowledge, this is the first study reporting implication of the combinational frequency of methylation and LOH at the *PTEN* gene region with the loss of *PTEN* protein in north Indian breast cancer patients. We are also among the first to evaluate *PTEN* protein expression status in defining clinical subgroups of Indian breast cancer patients. Our study defines a quadruple negative group with distinct features, hence, suggesting that more effective therapeutic strategies should be developed in TNBCs by considering these prognostic factors together in north Indian breast cancer patients.

In summary, our data suggest that along with the double hit, *PTEN* methylation and LOH are the independent mechanism of *PTEN* inactivation in a subset of Indian patients. We also suggest that a biological classification based on *PTEN* expression profile can truly enrich the targets in breast cancer. To boot, *PTEN* expression analysis for Indian breast cancer patients may be used as a cost-effective approach in distinguishing the more favorable group for a particular treatment.
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